Osteomark gets boost from Merck's Fosamax:
This article was originally published in Clinica
Executive Summary
US approval on October 2nd of Merck & Co's nonhormonal treatment for osteoporosis in post-menopausal women has been welcomed by Ostex which produces Osteomark, the first commercially available test to measure bone resorption. Trial data show that the Ostex test has potential use in monitoring patients' response to Fosamax therapy, says Dr B Gertz of Merck Research Laboratories and a member of the Ostex scientific advisory board.